By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...
Novavax (NASDAQ:NVAX) was downgraded to Underperform from Neutral at Bank of America, citing growth outlook challenges despite acknowledging the company’s strong execution and recent cost-cutting ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Gaithersburg company ...
Vaccine biotechnology company Novavax (NASDAQ:NVAX) in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s revenue to be around $1.05 billion, close ...
GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Wednesday reported second-quarter earnings of $106.5 million. On a per-share basis, the Gaithersburg, Maryland-based company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results